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Abstract 12 
Directed enzyme prodrug therapy is a form of cancer chemotherapy in which bacterial prodrug-13 
activating enzymes, or their encoding genes, are directed to the tumour before administration of a 14 
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prodrug. The prodrug can then be activated into a toxic drug at the tumour site, reducing off-target 1 
effects. The bacterial Nitroreductases are a class of enzymes used in this therapeutic approach and 2 
although very promising, the low turnover rate of prodrug by the most studied nitroreductase enzyme, 3 
NfnB from E. coli (NfnB_Ec), is a major limit to this technology. There is a continual search for 4 
enzymes with greater efficiency, and as part of the search for more efficient bacterial nitroreductase 5 
enzymes, two novel enzymes from Bacillus cereus (strain ATCC 14579) have been identified and 6 
shown to reduce the CB1954 (5-(Aziridin-1-yl)-2,4-dinitrobenzamide) prodrug to its respective 2’-and 7 
4’-hydroxylamine products. Both enzymes shared features characteristic of the Nitro-FMN-reductase 8 
Superfamily including non-covalently associated FMN, requirement for the NAD(P)H cofactor, 9 
homodimeric, could be inhibited by Dicoumarol (3,3'-methylenebis(4-hydroxy-2H-chromen-2-one), 10 
and displayed ping pong bi bi kinetics. Based on the biochemical characteristics and nucleotide 11 
alignment with other nitroreductase enzymes, one enzyme was named YdgI_Bc and the other 12 
YfkO_Bc. Both B. cereus enzymes had greater turnover for the CB1954 prodrug compared with 13 
NfnB_Ec, and in the presence of added NADPH cofactor, YfkO_Bc had superior cell killing ability, 14 
and produced mainly the 4’-hydroxylamine product at low prodrug concentration. The YfkO_Bc was 15 
identified as a promising candidate for future enzyme prodrug therapy.  16 
Key Words: Bacillus cereus, Nitroreductase, CB1954, prodrug therapy 17 
1. Introduction 18 
Chemotherapy is an important tool in the treatment of cancer and developing drugs or modalities with 19 
fewer side effects, but greater efficacy is a necessity. One approach to increase efficacy is to direct the 20 
treatment to the tumour, such as in directed enzyme prodrug therapy (DEPT). Bacterial Nitroreductases 21 
(NTRs) are a class of enzymes used in this therapeutic approach, and methods to direct these enzymes 22 
to solid tumours have included antibodies (ADEPT) [1], viruses (VDEPT) [2], polymers (PDEPT) [3], 23 
bacteria (BDEPT) [4], and metal nanoparticles (MNDEPT) [5]. 24 
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The most studied nitroreductase for DEPT is the E. coli NfsB (NfnB_Ec), which can convert the 1 
CB1954 prodrug (5-(Aziridin-1-yl)-2,4-dinitrobenzamide) to either the toxic 2’- or 4’-hydroxylamine 2 
metabolites, and positive clinical outcomes have been seen for prostate cancer [6], brain tumours [7], as 3 
well as for ovarian cancer cell lines [8]. The slow turn-over rate of the CB1954 prodrug (5-(Aziridin-1-4 
yl)-2,4-dinitrobenzamide) by NfnB_Ec, however still currently limits the therapeutic efficacy of DEPT 5 
[9].  6 
Attempts to improve the enzyme’s kinetic abilities by site-directed mutagenesis have resulted in 7 
substantial improvements [10, 11, 12]. Other approaches to overcoming the poor turnover of NfnB_Ec 8 
for CB1954, have included the identification of other bacterial nitroreductase enzymes [13, 14, 15], or 9 
producing CB1954 prodrug derivatives with greater potency, such as PR-104A [16, 17]. 10 
The majority of CB1954 prodrug activating enzymes isolated thus far are related to the NfsA and 11 
NfsB enzyme families, use either NADH or NADPH as an external electron donor, and are tightly 12 
associated with FMN or FAD cofactors. The NfsA and NfsB nitroreductase enzyme families can be 13 
inhibited with dicoumarol and are often found to be homodimers. Other enzyme families which have 14 
been shown to reduce the CB1954 prodrug include the NemA_Ec (Escherichia coli) [18, 12], AzoR_Ec 15 
[14, 12], MdaB_Ec [19, 12], and YwrO_Bs (Bacillus subtilis) [13, 20]. The latter enzymes have been 16 
less well characterised but they too require NAD(P)H cofactors and have a FMN/FAD prosthetic group.  17 
In the search for promising enzymes for MNDEPT, basic requirements include a high turnover for 18 
the CB1954 prodrug at low substrate concentrations and the preferred production of mainly the 4’- 19 
hydroxylamine metabolite. The 4’hydroxylamine derivative of CB1954 has been shown to be the more 20 
toxic metabolite [21], but has less of a bystander effect compared to the 2’- hydroxylamine [22].  21 
Although oxidoreductases have been isolated from a large number of bacterial species, very few have 22 
the required characteristics for DEPT {NfnB_Vv (Vibrio vulnificus), YfkO_Bs (Bacillus subtilis) [15], 23 
YfkO_Bl (Bacillus licheniformis) [23], a NfnB_Ec (Escherichia coli) mutant [24, 25, 26], and a Frase 24 
I_Vf (Vibrio fischeri) mutant [11]}. No Nitroreductases have been isolated from Bacillus cereus (a 25 
common environmental pathogen) [27, 28], even though a study using fluorogenic substrates, showed 26 
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B. cereus to produce one of the highest levels of reduced fluorogenic nitro-compounds, suggesting the 1 
presence of very effective oxidoreductases [29]. 2 
For this reason, the B. cereus (ATCC 14579) genome was searched for DNA sequences with high 3 
similarity to the nfnb_Ec gene, with the aim of cloning, expressing and characterising the proteins in 4 
terms of mechanism, NAD(P)H requirement, flavin content, pH and temperature stability, reduction of 5 
CB1954 prodrug, type of product formation, and ability to induce cell death in SK-OV-3 (Human 6 
Caucasian ovary adenocarcinoma cell line). This work set out to identify a promising nitroreductase 7 
from B. cereus for DEPT. 8 
    9 
2. Materials and Methods 10 
All chemicals were obtained from VWR (Lutterworth, UK) unless otherwise stated. 11 
2.1 Cloning of novel proteins. A nucleotide BLAST search of the Bacillus cereus (ATCC 14579) 12 
genome was performed using the nfnB gene sequence of Escherichia coli (gene ID: 945778). A gene 13 
with 33.1% identity to the nfnB gene was identified as BC_3024 (gene ID: 12053372), possibly 14 
encoding a NAD(P)H nitroreductase. Secondly, a putative Oxygen-insensitive NADPH nitroreductase 15 
was identified (BC_1619) with gene ID: 1203968, and thirdly, a putative nitroreductase family protein 16 
with 28.07% identity was selected (BC_1952, gene ID:1204301). Primers were designed using the free 17 
online tools, BioEdit (Ibis biosciences) and NetPrimer (Premier Biosoft International). All restriction 18 
enzymes (RE) were obtained from Promega (UK). 19 
To obtain DNA template, B. cereus was grown in nutrient broth (5 ml) overnight and genomic DNA 20 
isolated the next day using the WizardR Genomic DNA Purification Kit (Promega, UK). PCR was 21 
performed using the purified genomic DNA (in ultra-pure water) as template. Phusion High-Fidelity 22 
DNA polymerase kit (Thermo Scientific, UK) was used according to the manufacturer’s instructions. 23 
PCR products were purified using the QIAquick PCR Purification Kit (QIAGEN Ltd, UK) according to 24 
the manufacturer’s instructions. The purity and approximate size of the PCR products were confirmed 25 
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using agarose gel electrophoresis. Next the pure PCR products were subjected to restriction enzyme 1 
(RE) digests using the sites indicated in table 1, whilst the pET28a+ vector (Novagen, Merck, UK) was 2 
separately subjected to the same RE digests including an additional suicide cut using the EcoRI cut site. 3 
Digests were also purified using the QIAquick PCR Purification Kit (QIAGEN Ltd, UK) according to 4 
the manufacturer’s instructions.  5 
Table 1: Primers used for cloning of novel proteins from B. cereus 6 
Once purified, ligation between the digested PCR products and pET28a+ vector was performed using 7 
T4 DNA ligase (New England Biolabs, UK) at 16˚C overnight. To confirm successful ligation between 8 
the gene of interest and the plasmid vector, a PCR based on the T7 promoter and T7 terminator 9 
sequences, which flank the gene insert region contained within the vector, was performed using Taq 10 
DNA Polymerase Master Mix (Amplicon, Denmark) according to the manufacturer’s instructions. The 11 
recombinant plasmids containing the BC_3024, BC_1619, and BC_1952 genes were renamed 12 
pBC3024, pBC1619, and pBC1952.The plasmids were sequenced on an ABI 3730XL sequencing 13 
machine and corresponded to the sequences reported for whole genome sequencing [30]. For 14 
amplification of the recombinant plasmids, competent E. coli DH5 cells (200 l) were transformed 15 
with recombinant plasmid (~10 l) and incubated on agar plates containing Kanamycin (50 g/ml). The 16 
Kanamycin antibiotic is used to select for bacterial colonies containing the pET28a+ plasmid with the 17 
KanR gene.    18 
2.2 Expression of novel proteins. Recombinant plasmids pBC3024, pBC1619, and pBC1952 were 19 
transformed into E. coli Rosetta pLysS (Novagen, Merck, UK) competent cells and grown on agar 20 
plates containing Kanamycin (50g/ml) and 0.5% glucose. For expression, a single colony was first 21 
inoculated into 5 ml of Luria-Bertani (LB) broth/ Kan (50g/ml) / 0.5% glucose medium and grown at 22 
37˚C overnight. The next day, overnight culture (5 ml) was added to flasks containing LB broth/Kan 23 
/glucose (500 ml) and grown up to an OD of 0.6 at 37˚C with shaking at 180 rpm. Protein expression 24 
was induced by adding 2 ml of an IPTG (100 mM, isopropyl--D-thiogalactopyranoside) solution and 25 
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samples grown for a further 4 hours. As a control, IPTG would be omitted from one of the flasks. 1 
Cultures were then spun down at 8000 rpm (5400 x g) at 4˚C for 10 min, and pellets were resuspended 2 
in 10 ml of binding buffer (Potassium phosphate buffer [PB] 50 mM pH=7.2, 0.4 M NaCl, 10 mM 3 
Imidazole), and the supernatant containing the over-expressed proteins purified as previously described 4 
[31]. Briefly, over-expressed proteins  contain a His-tag for purification using metal ion affinity 5 
chromatography using Ni2+, and then eluted with Imidazole. The fractions containing purified protein 6 
where then subjected to PD10 columns for exchange chromatography to remove any impurities, mainly 7 
Imidazole. When the over-expressed proteins were insoluble, proteins were isolated from the cell debris 8 
by resuspending the pellets in a resuspension buffer (20 ml, 20 mM Tris-HCL, 0.5 M NaCl, pH=8.0), 9 
sonicated for 50 sec discontinuously, spun down at 8000 rpm (5400 x g) at 4˚C for 10 min, pellets 10 
resuspended in isolation buffer (15 ml, 20 mM Tris-HCL, 0.5 M NaCl, 2% Triton X-100, 12% w/v 11 
Urea, pH=8.0), spun down at 9000 rpm (7000 x g) at 4˚C for 10 min, and the supernatant containing the 12 
over-expressed proteins was then purified as described above [31]. The purity and molecular weight of 13 
the protein fractions were assessed after separation on a 12% SDS-PAGE gel during electrophoresis 14 
(Mini-PROTEAN Electrophoresis System, Bio-Rad), and visualized with Coomassie blue, before use 15 
in further experiments [32]. Protein concentration of purified protein was determined from a BSA 16 
standard curve using the ProPure Biuret protein assay (Amresco, NBS Biologicals, UK), according to 17 
the manufacturer’s instructions. Non-reducing SDS-page was performed as previously described [33]. 18 
2.3 Enzyme reactivity to CB1954 and cofactor requirement. Purified recombinant proteins 19 
were tested for reactivity to CB1954 by incubating varying amounts of recombinant protein with 20 
NAD(P)H (30 µl, 10 mM stock), CB1954 (10 µl, 10 mM stock), and PB (potassium phosphate buffer 21 
50 mM, pH= 7.2), and measuring absorbance spectra (600 nm - 200 nm) every 90 sec for 10 min on a 22 
Jasco V-550, UV/Vis spectrophotometer. Controls were run for prodrug, NAD(P)H, and enzyme as 23 
well. All spectra were analysed with the Spectra Manager Software. The specific activity of the purified 24 
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recombinant proteins was calculated using the molar absorptivity of CB1954 hydroxylamine products 1 
at 420 nm (ε=1200 M-1cm-1) [14]. 2 
2.4 Enzyme kinetics. To determine the kinetic parameters of the novel proteins with the CB1954 3 
prodrug, product formation was measured at 420 nm using the time-drive option on a microplate reader. 4 
Purified recombinant proteins (10 g/ml) were incubated with NAD(P)H (4 mM) in PB (50 mM, pH= 5 
7.2) at 37˚C for 3 min prior to adding increasing concentrations of CB1954 (50 M-5 mM), and 6 
measuring initial velocity for a total of 1 min. The DMSO solvent concentration was always kept 7 
constant at 5% v/v. The amount of product formed per second was calculated using change in 8 
absorbance during the first 30 sec and the molar absorptivity of the hydroxylamine products of CB1954 9 
(1200 M-1. cm-1). To determine the enzyme mechanism the enzymes were incubated with a constant 10 
CB1954 concentration (10 M - 150 M), whilst varying the NAD(P)H concentrations (250 M - 5 11 
mM). Hydroxylamine product formation was measured at 420 nm as mentioned above. To determine 12 
whether enzymes possessed flavin reductase activity, a constant concentration of enzyme (10 g/l) 13 
and FMN (10 M) was used, whilst varying the NAD(P)H added (250 M - 2 mM). The amount of 14 
FMN reduction was measured at 450 nm using the molar extinction coefficient of 12 500 M-1cm-1 [34]. 15 
Next, nonlinear regression analysis was performed on the rates of product formation (M/sec) vs 16 
substrate concentrations in SigmaPlot 12 (SPSS, (Systat Software Inc.) and Graphpad Prism 6, and the 17 
Michaelis-Menten constants determined.  18 
2.5 Inhibition kinetics. To determine the inhibition constants, UV-Vis scans were conducted using a 19 
96-well plate on a microplate reader with product formation measured at 420 nm. Each well of the plate 20 
contained a constant concentration of CB1954 (5 µl, 40 M and NTR (10 g/ml), with varying 21 
concentrations of NADH (20 µl, 500 µM – 1 600 M), at different concentrations of Dicoumarol (25 22 
µl, 0 M – 40 M). Total volume was made up to 100 µl with PB (50 mM, pH 7.2). The plates were 23 
incubated for 3 minutes at 37°C before enzyme was added and the plates were scanned. The amount of 24 
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product formed per second was calculated using the change of absorbance over 20 seconds and the 1 
molar extinction coefficient of the hydroxylamine derivatives at 420 nm (ε = 1200 M-1 cm-1). 2 
2.6 Temperature and pH profiles of the recombinant enzymes. Purified proteins were incubated 3 
with NAD(P)H (30 µl, 10 mM stock), and PB (50 mM) at increasing temperatures (15˚C-80˚C) for 3 4 
min, prior to adding CB1954 (10 µl, 10 mM stock) to the test and DMSO to the reference cell. For the 5 
pH stability, purified recombinant proteins were incubated with NAD(P)H (30 µl, 10 mM stock), in a 6 
range of phosphate buffers (pH=2 to pH=11) for 3 min at 30˚C before adding CB1954 (10 µl, 10 mM 7 
stock) to the test and DMSO to the reference cell. All absorbance spectra (600 nm - 200 nm) were 8 
recorded every 90 sec for 10 min on a Jasco V-550, UV/Vis spectrophotometer and analysed with the 9 
spectra manager software. 10 
2.7 Confirming the presence of FMN. The purified proteins were denatured with heat treatment at 11 
70°C for 20 min to liberate the bound FMN, followed by centrifugation at 10,000 X g for 20 min [35]. 12 
The supernatant was analysed by thin-layer chromatography (TLC) using a solvent system of Na2PO4 13 
and the developed plates were visualized under UV light at 366 nm.  14 
2.8 HPLC analysis on reaction products. The following components were added into a 15 ml 15 
Falcon tube covered in foil: 120 μl NAD(P)H (10 mM), 20 μl CB1954 (50 mM), enzyme 116 g/mL 16 
final concentration, and made up to a final volume of 1.080 ml with 50 mM PB (pH= 7.2). The reaction 17 
mixture was incubated at 25°C for 30 minutes. Prior to HPLC analysis the reaction mixture was de-18 
gassed using nitrogen (g) for 10min. Next, 600 μl of the de-gassed mixture was placed into a 19 
Chromacol Select 2 mL vial (2-SVW8-CP) and placed in an Ultimate 3000 UHPLC machine (thermo 20 
Scientific) using a reverse phase column. The solvent consisted of an acetonitrile/ water mixture, 21 
beginning with 10% acetonitrile and increasing by 1% per minute. After a 20 minute run this gradient 22 
increases to 40% acetonitrile per minute, reaching 100% after 22 minutes. Eluents were scanned at 4 23 
different wavelengths 260 nm, 300 nm, 350 nm, and 420 nm. Product peaks were identified after 24 
comparison with all reagents prior to the start of the enzymatic reaction. The ratios of the 4’-25 
hydroxylamine vs the 2’-hydroxylamine products were determined first using absorbance at 260nm 26 
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according to literature [15] and then using absorbance at 420nm, where both products have equal 1 
absorption [36]. 2 
2.9 In Vitro Cytotoxicity assays. The MTT assay was performed following the method of Mossman, 3 
1983 with slight modification. [37] Briefly, SK-OV-3 cells (Sigma Aldrich, United Kingdom) were 4 
seeded at a density of 1X104 cells per well, in 100 l Dulbecco’s Modified Eagles Medium (DMEM)  5 
containing 10% FBS and were allowed to attach overnight in a CO2 incubator. After 16 hours, medium 6 
was carefully flicked off, and 50 l of medium containing CB1954 (20 M) either in the presence or 7 
absence of NAD(P)H (200 M) was added. Next, medium containing a set amount of purified enzyme 8 
from section 2.2 (50 l) was added and after 4 h, the medium was removed and cells were replenished 9 
with complete DMEM (100 l). After 48h, 20 l of MTT (5 mg/ml) was added to each well and 10 
incubated at 37oC for 4 h. The purple formazan crystals formed were dissolved in 100 l of dimethyl 11 
sulfoxide after removing the media carefully and the absorbance was read at 570 nm in a microplate 12 
reader. 13 
3. Results  14 
3.1 Cloning and sequencing. Three Bacillus cereus genes were successfully amplified during PCR 15 
and inserted into the pET28a+ expression vector, which inserts an N-terminal Histidine-tag (his-tag) for 16 
ease of purification of the proteins. The plasmids containing the three B. cereus genes were sequenced, 17 
which confirmed the identity of the genes [30]. 18 
3.2 Expression of novel proteins. Preliminary expression experiments of the three B. cereus genes 19 
indicated that the addition of 0.5% glucose was beneficial [38] and incubation temperature of 37˚C 20 
gave good overexpression. The BC_1952 did not express well and was often found to accumulate with 21 
the cell debris, suggesting failure of the protein to fold correctly. All protein supernatants were bright 22 
yellow in colour when compared to supernatants of un-induced cultures. The yellow coloured solutions 23 
were subsequently purified using metal ion affinity chromatography (Ni2+) and his-tagged proteins 24 
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eluted with an Imidazole gradient (10 mM-500 mM). As seen from the denaturing SDS-PAGE in 1 
Figure 1 (Top), the BC_3024 enzyme eluted mainly at a concentration of 300 mM Imidazole (lane 8) as 2 
a single band with an approximate molecular weight of 27 kDa. The BC_3024 protein under non-3 
denaturing (native) conditions (Figure 1, Bottom) appeared to have a molecular weight between 55 and 4 
72 kDa, which is roughly twice the molecular mass seen in the denaturing gel. These results suggested 5 
that the protein was most likely a homodimer.  6 
The BC_1619 protein, as seen from the denaturing SDS-PAGE in Figure 2 (Top), eluted between 300 7 
mM and 500 mM Imidazole (lane 8 and 9) as a single band between 26 and 34 kDa. The BC_1619 8 
protein under non-denaturing (native) conditions (Figure 2, Bottom) gave an approximate molecular 9 
weight of 60 kDa, which is again roughly twice the molecular mass seen in the denaturing gel. These 10 
results implied that the BC_1619 was most likely also a homodimer.  11 
The BC_1952 protein was also eluted from the Ni2+ column using 300 mM and 500 mM Imidazole 12 
and appeared to migrate as a single band in denaturing PAGE roughly at 26 kDa (data not shown), and 13 
in a non-denaturing PAGE at above 55 kDa. The results suggested that BC_1952 was multimeric in its 14 
native form, but it could not be confirmed what the exact number of subunits or their size were. It is 15 
worth noting that the molecular weight of all the expressed recombinant proteins was approximately 3.6 16 
kDa greater than the predicted molecular mass based on the gene sequences alone, due to the presence 17 
of the His-Tag added during cloning. 18 
3.3 Presence of FMN. The yellow colour of the expressed protein solutions suggested that these 19 
proteins were associated with FMN [35]. To prove the association with FMN, TLC analysis was 20 
performed of denatured protein solutions and compared with a FMN and FAD standard (Figure 3). 21 
After enzyme denaturation, all three expressed enzymes, BC_3024, BC_1619, and BC_1952 appeared 22 
to have FMN present, although the FMN from the enzyme migrated slightly lower in TLC than the 23 
FMN standard. Furthermore, performing UV-Vis scans on the proteins showed absorption peaks 24 
around 460 nm, consistent with the presence of FMN [35]. 25 
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3.4 Enzyme reduction of CB1954 prodrug. It was next determined whether the three enzymes 1 
could reduce the CB1954 prodrug in presence of NAD(P)H cofactors. Prior to purification, crude 2 
extracts of BC_1952, BC_3024 and BC_1619 were assessed for their ability to reduce the CB1954 3 
prodrug in the presence of excess NAD(P)H. Full wavelength scans (200 nm – 600 nm) were obtained 4 
every minute for 10 minutes. Product formation was recorded at 420 nm. The BC_1952 enzyme 5 
showed little to no activity to the prodrug using either of the cofactors. Both BC_3024 and BC_1619 6 
cell extracts showed reductase activity. Purified BC_3024 reduced the prodrug to products which 7 
absorbed at 420 nm using either NADH or NADPH as cofactor. The BC_1619 enzyme could also 8 
reduce the CB9154 prodrug, using either NADH or NADPH, but had preference for the NADPH 9 
cofactor. In the absence of either enzyme, cofactor or prodrug, no nitro-reduction occurred. The 10 
BC_1952 enzyme was additionally tested with TNT and dinitrobenzamide, but did not show significant 11 
activity and BC_1952 was abandoned at this point and no further experiments performed, but may 12 
require further characterisation in the future.  13 
3.5 Temperature and pH profiles. Prior to determining the kinetics of the two active B. cereus 14 
enzymes, the temperature and pH profiles were determined. The BC_3024 enzyme reduced CB1954 15 
prodrug at a broad range of temperatures; the optimum being between 30-40˚C (data not shown). 16 
Enzyme activity decreased significantly above 50° C, and the enzyme was stable at pH 5 to 9; the 17 
optimum at pH=7 (data not shown). The BC_1619 enzyme reduced prodrug optimally between 30 and 18 
40˚C, but lost activity at temperatures above 50˚C. Compared to BC_3024, BC_1619 had a narrower 19 
pH range and the optimum was around pH=7.4 (data not shown).  20 
3.6 Enzyme kinetics. The kinetic parameters of the two novel enzymes for CB1954 were determined 21 
using the absorbance of the hydroxylamine products measured at 420 nm in UV-Vis spectroscopy and 22 
data was analysed using SigmaPlot 12 and Graphpad Prism 6. Results are summarised in Table 2.  23 
s seen in Table 2, the BC_3024 enzyme had a turnover for CB1954 (45 s-1) using NADPH, which is 24 
greater than that of NfnB_Ec (25 s-1) [14]. The novel enzyme also had a lower Km (2700 M compared 25 
to 4060 M for NfnB), and greater efficiency (16,760 M-1 s-1 compared to 6180 M-1 s-1 for NfnB, Table 26 
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2). The BC_3024 enzyme could use both NADH and NADPH as cofactor, and based on turnover, 1 
showed slight preference for NADH, The enzyme had limited FMN reductase activity.  2 
The kinetic analysis for BC_1619 (Table 2) gave a turnover of 60 s-1 for CB1954, and a Km of 3 
2800 M. However, BC_1619 used NADPH as the preferred cofactor based on the turnover, and had 4 
greater FMN reduction, compared to BC_3024. 5 
3.7 Analysis of reaction products. Using NfnB_Ec as a model enzyme, CB1954 reduction 6 
products were identified in HPLC initially using absorbance at 260nm [15], and corresponding this with 7 
the absorbance at 420nm for validation of a new approach. As seen from Figure 4, Both the 4’-8 
hydroxylamine (4.8-5.5 min) and 2’-hydroxylamine (9.5 -11.4 min) products were detected at 420nm as 9 
well as the presumed amino derivates ( after 15 min). By directly comparing the areas under the curves 10 
for the two product peaks at 420 nm [36], the ratio of 4’-hydroxylamine vs 2’-hydroxylamine was 11 
determined to be 49: 51. This correlated very well with what has previously been described for 12 
NfnB_Ec using absorbance at 260nm and separate molar extinction coefficients [15]. 13 
Applying the 420 nm analysis of NfnB products to the HPLC chromatogram for BC_3024 14 
(Figure 5), the CB1954 reduction products were identified, and it was determined that the 2’-15 
hydroxylamine (9.5-11.5 min) was major product. The 4’hydroxylamine (5 min) was the minor 16 
product. It was determined that the ratio of 4’-hydroxylamine vs 2’-hydroxylamine was 14: 86 17 
produced by BC_3024 (Figure 5). An additional two products were also detected downstream of the 18 
hydroxylamines, and these were thought to be the 4’-amino and 2’-amino derivatives, which are either 19 
end products of enzyme catalysis, or non-enzymatic rearrangements [39]. To the contrary, the BC_1619 20 
enzyme produced more of the 4’-hydroxylamine product in a ratio of 67: 33 (4’ vs 2’-hydroxylamine) 21 
(Figure 6).  22 
3.8 Inhibition kinetics. The Dixon plot and double reciprocal plots were used as an initial 23 
indications of the type of inhibition that Dicoumarol may have on NADH binding to the novel enzymes 24 
[40].The Dixon plot for BC_3024 (Figure 7) suggested uncompetitive inhibition, but the double 25 
reciprocal plot (data not shown) suggested competitive inhibition. Taken together, these graphical 26 
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results would suggest a case of mixed inhibition. Simultaneous nonlinear regression (SNLR) has been 1 
shown to be more accurate for determining inhibition types and kinetic parameters compared with 2 
graphical methods and kinetic parameters for BC_3024 were determined using Graphpad Prism version 3 
6 (Table 3) [41]. 4 
Using the mixed inhibition model in Graphpad, which compares competitive, non-competitive 5 
and uncompetitive models, it was shown that the data for BC_3024 was best described with the 6 
uncompetitive inhibition model in which the 0< <1. This was achieved using a 95% confidence 7 
interval and all curves had R square values of 0.91- 0.99. Both the Vmax and Km for NADH were 8 
decreased by the presence of Dicoumarol (Table 3) providing support for an uncompetitive inhibition 9 
type. However, according to literature [42], it is very rare for the inhibitor to only bind to the enzyme-10 
substrate complex and is more a case of preference, in which the affinity of Dicoumarol for enzyme-11 
substrate complex is greater than affinity for enzyme alone. Under the conditions tested here, the 12 
Dicoumarol inhibitor preferentially bound to the BC_3024 enzyme-substrate complex, such that the 13 
association constants were estimated to be Ki[ES]= 23 M and Ki[E]= 70 M. Uncompetitive 14 
inhibition of NADH by Dicoumarol has however not been reported for other nitroreductases. 15 
The Dixon plot (Figure 8) for the BC_1619 enzyme suggested that the binding of NADPH was 16 
competitively inhibited by Dicoumarol, as for most nitroreductases reported in literature. To confirm 17 
this and determine the kinetic parameters, SNLR was performed using Graphpad Prism 6, which 18 
showed Km to increase slightly in presence of inhibitor (Table 3), while Vmax remained constant. The 19 
inhibition constant (Ki[E]) was determined to be 2095 M. 20 
 The SNLR results for BC_1619 confirmed competitive inhibition, in which the inhibitor 21 
competes for binding to the same form of the enzyme as the substrate and at high enough substrate 22 
concentrations, Vmax can still be achieved.  23 
3.9 Enzyme mechanism. Double reciprocal plots of initial velocity at different NAD(P)H or 24 
CB1954 concentrations were analysed and are presented in Figure 9 [43]. 25 
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Firstly, it has been shown here that the BC_3024 enzyme converts CB1954 into either the 4’-1 
hydroxylamine or the 2’-hydroxylamine products using NADH/ or NADPH as electron donor. Thus, 2 
there are two substrates (CB1954 and NAD(P)H) and two products (a hydroxylamine/ or amino and 3 
NAD(P)+), which makes it a bi bi reaction. Furthermore, the parallel lines obtained in the double 4 
reciprocal plots of 1/ vs 1/[NADH] (Figure 9, A) and 1/ vs 1/[CB1954] (Figure 9, C), indicated that 5 
the enzyme follows an ping pong bi bi mechanism, which means that the first product needs to 6 
dissociate from the enzyme, before the second substrate will bind [42]. 7 
      8 
Similarly, the BC_1619 consists of a two substrate and two product reaction (bi bi) and also produced 9 
parallel lines in the double reciprocal plots for 1/ vs 1/[NADH] (Figure 9, B) and 1/ vs 1/[CB1954] 10 
(Figure 9, D), which is characteristic of a ping pong bi bi mechanism [42]. 11 
3.10 Cell toxicity studies. Percentage cell survival of SK-OV-3 cells was determined in presence of 12 
increasing enzyme concentration, a constant concentration of prodrug (10 M), and the presence or 13 
absence of added NAD(P)H cofactor. As controls, cells were incubated with medium only, enzyme 14 
only, or prodrug only (Figure 10).  15 
As seen from Figure 10, no significant cell death was caused by the combination of BC_3024 and 16 
CB1954 in absence of added cofactor. In the presence of added NADH, percentage cell kill was 26%, 17 
but this enzyme could not improve on the cell killing of NfnB_Ec, which achieved up to 40% cell 18 
killing (data not shown). Greater cell killing of BC_3024 was observed in the presence of increasing 19 
CB1954 concentrations (data not shown), but this would not be of benefit clinically.  20 
To the contrary, the BC_1619 enzyme and CB1954 in the presence of NADPH induced a significant 21 
decrease in cell survival (60%, Figure 11), similar to that seen for NfsA_Ec [15]. In absence of added 22 
cofactor however, BC_1619 and CB1954 could not cause significant cell killing (Figure 11). Also seen 23 
from Figure 11, there is a decrease in cell killing at higher concentrations of BC_1619 enzyme, which 24 
appears to be contradictory. However, this phenomenon has been well described in literature and is 25 
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known as the Hormetic effect [44], in which the dose-response curve shows cell sensitivity at low 1 
concentrations, but not at higher concentrations of agent. Also seen from both Figures 10 and 11, was 2 
that neither the enzymes nor the cofactor alone could cause significant cell death. 3 
4. Discussion 4 
The major aim of this research was to identify, clone and express novel proteins from B. cereus 5 
which had features similar to that of the E.coli NfnB protein and assess their ability to reduce the 6 
CB1954 prodrug and cause cell death in a cancer cell line. It was hoped that at least one of the novel 7 
proteins would be a suitable candidate for use in our novel enzyme prodrug therapy (MNDEPT) [5].  8 
All the aims were achieved and three B. cereus proteins were successfully cloned, expressed and 9 
purified, and all of those were tightly associated with FMN (Figure 3) and appeared to be homodimers, 10 
just like NfnB_Ec [45]. One of the proteins (BC_1952) though, was not active with prodrug or any 11 
other compound (TNT and Dinitrobenzamide, data not shown) using either NADH or NADPH. Due to 12 
the difficulty in purifying this enzyme, it was hypothesised that poor activity was due to misfolding or 13 
instability. For the purpose of this work, the BC_1952 protein was not further investigated, but 14 
attention shifted to the BC_1619 and BC_3024 proteins. Both of the last mentioned proteins had 15 
superior enzyme kinetics to the CB1954 prodrug compared with native NfnB_Ec (Table 2) [13]. The 16 
BC_1619 enzyme preferred NADPH and was competitively inhibited by dicoumarol (Figure 7), 17 
similarly to the nitroreductase from Enterobacter cloacea [Error! Bookmark not defined.]. 18 
The Dixon plot for inhibition of the BC_3024 enzyme showed that NADH binding was both 19 
competitively and uncompetitively inhibited, suggesting mixed inhibition (Figure 7). However, SNLR 20 
indicated that the data was best fit using the uncompetitive inhibition model, which is different from 21 
any nitroreductase reported to date. A possible explanation for the differences seen here for the 22 
BC_3024 enzyme could be explained based on crystal structure analysis of the most studied 23 
nitroreductase (NfnB_Ec) [46]. It has been shown with NfnB_Ec, that there are two channels in the 24 
protein which lead to the active site. For NfnB_Ec, NADH and CB1954 prefer the A-channel because 25 
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available space, but the B-channel is blocked by a Phe124 residue. Thus for NfnB, there appears really 1 
only one option for Dicoumarol, and that is to compete with the NADH for binding to the A-channel. 2 
However, it could be that BC_3024 has a slightly different active site conformation in which 3 
both A- and B- channels are open for substrate binding. A possible explanation for the uncompetitive 4 
inhibition seen here, is that the larger NADH has a preference for the A-channel, leaving Dicoumarol to 5 
bind preferentially to the smaller B-channel. Thus, this would result in Dicoumarol binding to the 6 
enzyme-NADH complex and causing uncompetitive inhibition. Computational modelling and 7 
crystallisation was however not in the scope of this research and may be worth investigating in the 8 
future. 9 
As part of the enzyme characterisation, double reciprocal plots of initial velocities (Figure 9) were 10 
used to determine enzyme mechanism [Error! Bookmark not defined.]. It was shown that both the 11 
BC_1619 and BC_3024 enzymes followed a ping pong bi bi reaction mechanism . Taken together, the 12 
two novel proteins from B. cereus were classified as oxygen-insensitive nitroreductases, based on the 13 
following characteristics: reduce nitro-groups to hydroxylamine derivatives in presence of oxygen; 14 
follow a ping pong bi bi mechanism; require NADH or NADPH as cofactors; are homodimers; contain 15 
a FMN prosthetic group; and are strongly inhibited by dicoumarol [47, 48, 49]. 16 
In order to decide on names that most closely described the two novel proteins, both homology 17 
searching and biochemical characterisations were used to rename the B. cereus enzymes. The BC_3024 18 
enzyme shared highest identity (69%) to the YdgI enzyme from Bacillus subtilis (YdgI_Bs) using the 19 
predicted amino acid sequence (DELTA-BLAST, NCBI database). Similarly to the YdgI_Bs, BC_3024 20 
had a preference for NADH and produced more of the 2’-hydroxylamine product compared to the 4’-21 
hydroxylamine [13]. It was for this reason that BC_3024 from Bacillus cereus was renamed as 22 
YdgI_Bc.  23 
The BC_1619 sequence contains the NfsA_FRP region and was shown to share highest identity with 24 
the Nfra1-nitroreductase protein (42%) from B. subtilis, when searching the NCBI protein database 25 
(PDB). Different from its closest relative however (Figure 6), BC_1619 produced more of the 4’-26 
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hydroxylamine than the 2’-hydroxylamine product upon reduction of CB1954, and had very different 1 
kinetic parameters. When comparing evolutionary relatedness, it was noted that BC_1619 was distantly 2 
related to YfkO_Bs (Figure 12), with which it shares most, if not all biochemical similarities. YfkO_Bs 3 
produces CB1954 hydroxylamine reduction products in a ratio of 75: 25 (4’ vs 2’), whilst BC_1619 4 
produces them in a ratio of 67: 33. Furthermore, YfkO_Bs also prefers NADPH as cofactor and 5 
produces CB1954 kinetic parameters almost identical to that of BC_1619 [13]. It was thus decided to 6 
rename BC_1619 as YfkO_Bc [NAD(P)H Nitroreductase from Bacillus cereus]. 7 
Apart from characterising new proteins from B. cereus, this article also describes a new approach to 8 
determining the identity and amount of CB1954 reduction products using HPLC. To date, literature has 9 
used the absorbance at 260 nm to determine the amount and the ratio of each hydroxylamine product 10 
during HPLC analysis using the individual molar absorptivity constants for each product [15]. It is 11 
however known that both CB1954 hydroxylamine products have the same molar absorptivity at 420 nm 12 
[15], and that at this wavelength the greatest distinction between the 2’-and 4’-hydroxylamine peaks 13 
was seen. Using the solvent system described here, it was found that the 4’- hydroxylamine eluted 14 
around 5 min, whereas the 2’-hydroxylamine eluted between 9.5-11.4 min (Figure 5 and 6). To 15 
determine molar ratio of products produced, areas under the identified curves were directly compared. 16 
Our method was verified by comparing HPLC data for NfnB_Ec (Figure 4) and YfkO_B. licheniformis 17 
(data not shown) with results from literature [50, 23]. 18 
 Finally, to determine whether a new enzyme has promise for use in DEPT using the CB1954 19 
prodrug, it needs to have some basic characteristics, such as a high turnover for prodrug at low 20 
substrate concentrations, and the production of the more toxic 4’hydroxylamine metabolite. It is worth 21 
noting that although the 4’hydroxylamine derivative of CB1954 is more toxic [51], it has less of a 22 
bystander effect compared to the 2’-hydroxylamine [52].  23 
Both the novel enzymes assessed here (YdgI_Bc and YfkO_Bc), had the above mentioned 24 
characteristics (Table 2, Figure 5 and 6). However, in 2D cell culture YdgI_Bc was not very effective at 25 
inducing SK-OV-3 cell death in the presence of CB1954 prodrug either in absence or presence of added 26 
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NADH cofactor (Figure 10). The YfkO_Bc however, was much more effective at inducing SK-OV-3 1 
cell death in the presence of added cofactor (Figure 11), compared with native NfnB_Ec (data not 2 
shown). These results confirmed that YfkO_Bc was a promising candidate for DEPT.   3 
In conclusion, two novel enzymes from B. cereus have been isolated, characterised and re-named. 4 
Also a modified HPLC method for determination of CB1954 reduction products has been described and 5 
kinetic parameters were determined using the latest methodology (SNLR). Furthermore, the YfkO_Bc 6 
has been shown to be an excellent candidate for DEPT in that it has a high turnover for CB1954 at low 7 
substrate concentrations, produces mainly the 4’hydroxylamine product, is active at physiological pH, 8 
and induces significant SK-OV-3 cancer cell death in presence of NADPH. It is envisaged, that once 9 
the YfkO_Bc enzyme is immobilised onto gold-coated magnetic nanoparticles and directed to the 10 
cytoplasm of targeted cells (MNDEPT), this enzyme-prodrug combination will surpass the currently 11 
investigated DEPT approaches.   12 
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Figure 1: Showing a denaturing PAGE (Top) and non-denaturing PAGE (Bottom) of BC_3024 
fractions after metal ion affinity separation. Top, Lane 1( EZ-Run prestained protein ladder), Lane 2 
(supernatant), Lane 3 (flow through), Lane 4 (10 mM Imidazole), Lane 5 (50 mM Imidazole), Lane 6 
(100 mM Imidazole), Lane 7 (200 mM Imidazole), Lane 8 (300 mM Imidazole), Lane 9 (500 mM 
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Imidazole), Lane 10 (protein ladder). Bottom, Lane 1( EZ-Run prestained protein ladder), pure 
BC_3024 in lane 7. 
 
Figure 2: Showing a denaturing PAGE (Top) and non-denaturing PAGE (Bottom) of BC_1619 
fractions after metal ion affinity separation. Top, Lane 1( EZ-Run prestained protein ladder), Lane 2 
(supernatant), Lane 3 (flow through), Lane 4 (10 mM Imidazole), Lane 5 (50 mM Imidazole), Lane 6 
(100 mM Imidazole), Lane 7 (200 mM Imidazole), Lane 8 (300 mM Imidazole), Lane 9 (500 mM 
Imidazole), Lane 10 (protein ladder). Bottom, Lane 1( EZ-Run prestained protein ladder), Lanes 3-6 
purified BC_1619. 
Figure 3: TLC analysis of denatured proteins BC_1619, BC_1952, and BC_3024 as visualised 
under UV and compared with the migration of FMN and FAD standards. 
Table 2: Kinetic parameters of NfnB_Ec, BC_3024, and BC_1619 together with CB1954, 
NAD(P)H, and FMN 
Figure 4: A) HPLC chromatogram of a reaction mixture in the absence of NfnB_Ec, and (B) presence 
of NfnB_Ec enzyme. Using absorbance at 420 nm, NADH and phosphate buffer was detected at 2- 3.5 
min and the unreacted CB1954 prodrug at 11.5- 15 min in all chromatograms. In the presence of 
BC_3024, both the 4’-hydroxylamine and 2’-hydroxylamine products were detected at around 5 min 
and 10 min respectively. The products, which eluted after 15 min, were assumed to be the 4’-amino and 
2’-amino derivatives due to lower polarity compared to the hydroxylamines. Using the area under the 
curves (mAU*min) the amount of product produced was calculated and gave a ratio of 14: 86 (4’:2’-
hydroxylamine). 
 
Figure 5: A) HPLC chromatogram of a reaction mixture in the absence of BC_3024, and (B) presence 
of BC_3024 enzyme. Using absorbance at 420 nm, NADH and phosphate buffer was detected at 2- 3.5 
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min and the unreacted CB1954 prodrug at 11.5- 15 min in all chromatograms. In the presence of 
BC_3024, both the 4’-hydroxylamine and 2’-hydroxylamine products were detected at around 5 min 
and 10 min respectively. The products, which eluted after 15 min, were assumed to be the 4’-amino and 
2’-amino derivatives due to lower polarity compared to the hydroxylamines. Using the area under the 
curves (mAU*min) the amount of product produced was calculated and gave a ratio of 14: 86 (4’:2’-
hydroxylamine). 
 
Figure 6: A) HPLC chromatogram of a reaction mixture in the absence of BC_1619, and (B) presence 
of BC_1619 enzyme. Using absorbance at 420 nm, NADPH and phosphate buffer was detected at 2- 
3.5 min and the unreacted CB1954 prodrug at 11.5- 15 min in all chromatograms. In the presence of 
BC_1619, both the 4’-hydroxylamine and 2’-hydroxylamine products were detected at around 5 min 
and 10- 11.5 min respectively. The products, which eluted after 15 min, were assumed to be the 4’-
amino and 2’-amino derivatives due to lower polarity compared to the hydroxylamines. Using the area 
under the curves (mAU*min) the amount of product was calculated and gave a ratio of 67: 33 (4’:2’-
hydroxylamine). 
 
Figure 7: Dixon plot for BC_3024. The concentration of inhibitor (Dicoumarol) is plotted against the 
inverse rate of product formation in the presence of different concentrations of NADH. All data points 
are the average of three repeats and trendlines are linear best fit. All trendlines are roughly parallel 
suggesting that inhibition by Dicoumarol is uncompetitive for this enzyme.  
Table 3: Kinetics constants for BC_3024 and BC_1619 in presence and absence of different 
Dicoumarol concentrations 
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Figure 8: Dixon plot for BC_1619. The concentration of inhibitor is plotted against the inverse rate 
of prodrug reduction in the presence of different concentrations of NADPH. Each data point represents 
the average of three repeats and best fit linear lines. The converging lines around the origin suggests 
that the inhibitor is competitively inhibiting NADPH binding to the enzyme. 
Figure 9: Double-reciprocal plots of initial velocities obtained at various concentrations of CB1954, 
and varying concentrations of NAD(P)H. A and C) BC_3024 and BC_1619 respectively produced 
roughly parallel lines when plotting 1/ vs 1/NADH at varying CB1954 concentrations. B and D) 
BC_3024 and BC_1619 respectively produced roughly parallel lines when plotting 1/ vs 1/CB1954 at 
varying NAD(P)H concentrationsTaken together, these results suggested that these enzymes operate 
with a ping-pong mechanism. All data was the result of three repeats and trendlines represented linear 
best fit. 
 
Figure 10: Percentage cell survival of SK-OV-3 cells after a 4h incubation with culture medium 
only, enzyme only, prodrug only, and increasing concentrations of BC_3024 (25 nM to 200 nM) either 
in presence or absence of NADH (200 M). All data points represent at least 3 repeats and error bars 
indicate the standard deviation. 
Figure 11: Percentage cell survival of SK-OV-3 cells after a 4h incubation with buffer only, enzyme 
only, prodrug only, and increasing concentrations of BC_1619 (25 nM to 200 nM) either in presence or 
absence of NADPH (200 M). All data points represent at least 3 repeats and error bars indicate the 
standard deviation. 
Figure 12: Phylogenetic tree generated after a multiple alignment of nitroreductases (ClustalW2) to 
determine the relatedness of BC_1619 and BC_3024 to some common nitroreductases (NTR) and 
NTR-families. The results show that BC_1619 and BC_3024 fall within the oxygen-insensitive 
nitroreductase family. 
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Table 1 Primers used for cloning of novel proteins. 
Gene Primer 
sequence in 5′ 
to 3′ direction 
  RE 
BC_3024 Forward ATAGGATCCATGACTAACTCAGTAAAGAC BamHI 
BC_3024 Reverse ATCAAGCTTTTATTTCCATTCAGCAAC HindIII 
BC_1619 Forward ATAGGATCCATGACTAACTCAGTAAAGAC BamHI 
BC_1619 Reverse ATCAAGCTTTTATTTCCATTCAGCAAC HindIII 
BC_1952 Forward ATAGGATCCATGATGGCAAAGGATTTCTACTCC BamHI 
BC_1952 Reverse ATAAAGCTTCGATGGTGAACAGGTTATATTCC HindIII 
Underlined sections indicate the location and sequence of the restriction enzyme (RE) used. 
 
 
 
 
Table 2 Kinetic parameters of novel enzymes with CB1954, NAD(P)H, and FMN. 
Enzyme Variable Constant Vmax 
uM/s 
Km 
uM 
Kcat 
s−1 
Kcat/Km 
M−1s−1 
BC_3024 CB1954 NADH 8.32 2683.63 44.98 16 760 
  CB1954 NADPH 5.36 1642.06 28.95 17 630 
  NADH FMN N/A N/A N/A N/A 
BC_1619 CB1954 NADPH 9.76 2848.55 62.17 21 820 
  CB1954 NADH 2.97 868.29 18.91 21 780 
  NADPH FMN 0.24 204.75 1.49 7 300 
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Table 3 Kinetics constants for BC_3024 and BC_1619 in presence and absence of different Dicoumarol 
concentrations. 
Enzyme Variable Constant Dicoumarol Vmax 
uM/s 
Km 
uM 
αKi/ Ki μM 
BC_3024 NADH CB1954 0 μM 15.19 7595 NA 
BC_3024 NADH CB1954 5- 40 μM 8 4732 41.6 
BC_1619 NADH CB1954 0 μM 4.968 737 NA 
BC_1619 NADH CB1954 5- 40 μM 4.968 751 2095 
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